RecruitingPhase 2NCT07269470

Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

Sponsor

M.D. Anderson Cancer Center

Enrollment

40 participants

Start Date

Jul 13, 2026

Study Type

INTERVENTIONAL

Conditions

Chronic Myeloid Leukemia

Summary

The goal of this clinical research study is to find out if treatment with a combination of dasatinib plus ropeginterferon can help to control CML-CP. The safety of this combination will also be studied.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Dasatinib and a drug called Ropeginterferon alfa-2b (P1101) for people with chronic myeloid leukemia. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.